Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Tokyo, TokyoFounded 18932,858 employeesWebsite
A leading Japanese pharmaceutical company specializing in prescription Kampo medicines. It manages research, quality control, manufacturing, and sales, and holds a strong position in the medical market.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Domestic Market Business | 84% | ¥161.2B | ¥35.0B | 21.7% |
| China Business | 16% | ¥31.4B | ¥195M | 0.6% |
Close (Oct 30, 2026)
¥3,821+9.2% (1Y)
Tsumura +9.2% over 1Y, 3.5pt below the industry average (23 companies, +12.7%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥192.6B | ¥35.2B | ¥28.1B | ¥592.8B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
